Mitochondria Targeting Kills Cancer Cell without Acquired Drug Resistance
Achieves high selectivity in mitochondrial targeting of cancer cell;The first example to integrate subcellular targeting and spatial control of the assemblies of non-specific cytotoxic agents by EISA as a promising molecular process for selectively killing cancer cells;A new way for developing efficient nanomedicine without inducing acquired drug resistance.
The invention introduces a novel method to target organelles by modulating the redox potential of mitochondria and ultimately serve as a therapeutic approach to cancer and other immune-deficient disease. This bioinspired system is achieved by utilizing enzyme-instructed self-assembly (EISA) to kill cancer cells that minimizes acquired drug resistance.
United States
PCT/US2018/012359
美国
